Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.

Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J.

BMC Cancer. 2018 Mar 1;18(1):239. doi: 10.1186/s12885-018-4131-1.

2.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
3.

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.

Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Review. Erratum in: Pharmacotherapy. 2015 Dec;35(12):1205.

PMID:
26497482
4.

Immunothérapie des glioblastomes.

Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C.

Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Review. French.

PMID:
30595200
5.

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL.

J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.

PMID:
28901560
6.

Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.

Roth P, Valavanis A, Weller M.

Neuro Oncol. 2017 Mar 1;19(3):454-456. doi: 10.1093/neuonc/now265. No abstract available.

7.

Mechanistic and pharmacologic insights on immune checkpoint inhibitors.

Sweis RF, Luke JJ.

Pharmacol Res. 2017 Jun;120:1-9. doi: 10.1016/j.phrs.2017.03.012. Epub 2017 Mar 18. Review.

8.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R.

Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Review.

PMID:
28550712
9.

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Farina MS, Lundgren KT, Bellmunt J.

Drugs. 2017 Jul;77(10):1077-1089. doi: 10.1007/s40265-017-0748-7. Review.

PMID:
28493171
10.

Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.

Herz S, Höfer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, Ugurel S, Roesch A, Livingstone E, Schilling B, Franklin C.

Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8.

PMID:
27614165
11.

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.

Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA.

J Oncol Pharm Pract. 2015 Dec;21(6):451-67. doi: 10.1177/1078155214538087. Epub 2014 Jun 9. Review.

PMID:
24917416
12.

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.

Qin L, Li X, Stroiney A, Qu J, Helgager J, Reardon DA, Young GS.

Neuroradiology. 2017 Feb;59(2):135-145. doi: 10.1007/s00234-016-1769-8. Epub 2017 Jan 9.

13.

Immunotherapy-associated autoimmune hemolytic anemia.

Khan U, Ali F, Khurram MS, Zaka A, Hadid T.

J Immunother Cancer. 2017 Feb 21;5:15. doi: 10.1186/s40425-017-0214-9. eCollection 2017.

14.

Emerging role of checkpoint inhibition in localized bladder cancer.

Singh P, Black P.

Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21. Review.

PMID:
27776977
15.

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.

Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi H, Li J.

J Neurooncol. 2017 Jul;133(3):595-602. doi: 10.1007/s11060-017-2470-4. Epub 2017 May 12.

PMID:
28500560
16.

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Saha D, Martuza RL, Rabkin SD.

Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006.

17.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
18.

A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.

Levine O, Devji T, Xie F.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1765-1767. doi: 10.1080/21645515.2017.1322241. Epub 2017 May 8.

19.

Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Spain L, Larkin J.

Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6. No abstract available.

20.

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Atkins MB, Clark JI, Quinn DI.

Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Review.

PMID:
28383639

Supplemental Content

Support Center